* Lisata Therapeutics Inc LSTA.OQ reported a quarterly
adjusted
loss of 59 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -65 cents. The mean expectation of two analysts
for the quarter was for a loss of 75 cents per share. Wall
Street expected results to range from -77 cents to -73 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Lisata Therapeutics Inc's reported EPS for the quarter was
a
loss of 59 cents.
* The company reported a quarterly loss of $4.93 million.
* Lisata Therapeutics Inc shares had fallen by 3.3% this
quarter and gained 6.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Lisata
Therapeutics Inc is $14.00
This summary was machine generated from LSEG data November 13 at
12:07 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.75 -0.59 Beat
Jun. 30 2024 -0.76 -0.61 Beat
Mar. 31 2024 -0.72 -0.65 Beat
Dec. 31 2023 -0.89 -0.66 Beat